Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UROV Urovant Sciences (UROV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Urovant Sciences Stock (NASDAQ:UROV) 30 days 90 days 365 days Advanced Chart Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Get Urovant Sciences alerts:Sign Up Key Stats Today's Range$16.24▼$16.2450-Day Range$16.19▼$16.2452-Week Range$7.15▼$16.26VolumeN/AAverage Volume114,469 shsMarket Capitalization$531.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.Read More… Strange: Why is Amazon suddenly yielding 39.70%? (Ad)Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Receive UROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address UROV Stock News HeadlinesXavier Creative House Appoints Jami Rogers as VP of Sales & MarketingNovember 4, 2024 | msn.comXavier Creative House Hires Jami Rogers as Vice President of Sales & MarketingOctober 29, 2024 | finance.yahoo.comThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.November 17, 2024 | WealthPress (Ad)Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndromeApril 26, 2024 | finanznachrichten.dePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndromeApril 26, 2024 | finance.yahoo.comA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of DirectorsMarch 26, 2024 | finance.yahoo.comPetauri™ Elects William Fleming and James Robinson to Its Board of DirectorsDecember 6, 2023 | finance.yahoo.comPM360 Announces 2023 Trailblazer Award WinnersOctober 4, 2023 | finance.yahoo.comSee More Headlines UROV Stock Analysis - Frequently Asked Questions How were Urovant Sciences' earnings last quarter? Urovant Sciences Ltd. (NASDAQ:UROV) announced its quarterly earnings results on Thursday, February, 11th. The company reported ($1.46) EPS for the quarter, beating analysts' consensus estimates of ($1.59) by $0.13. When did Urovant Sciences IPO? Urovant Sciences (UROV) raised $150 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO. What other stocks do shareholders of Urovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO). Company Calendar Last Earnings2/11/2021Today11/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UROV CUSIPN/A CIK1740547 Webwww.urovant.com Phone44-0-20-7400-3347FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,740,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.90% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.90) per share Price / Book-8.55Miscellaneous Outstanding Shares32,743,000Free FloatN/AMarket Cap$531.75 million OptionableNot Optionable Beta2.36 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:UROV) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Urovant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
